Bresson-Hadni S, Franza A, Miguet J P, Vuitton D A, Lenys D, Monnet E, Landecy G, Paintaud G, Rohmer P, Becker M C
Unité de Transplantation Hépatique, C.H.U., Besançon, France.
Hepatology. 1991 Jun;13(6):1061-70.
Between 1986 and 1989, orthotopic liver transplantations were performed in our unit for 17 patients with incurable alveolar echinococcosis. Ten patients had hilar involvement (group I), and seven patients had posterior localization (five of them had chronic Budd-Chiari syndrome) (group II). The delay between diagnosis and the orthotopic liver transplantation was more than 48 mo in group Ia (six patients), less than 24 mo in group Ib (four patients) and less than 48 mo in group II. Previous operations were more common in group Ia than in group Ib and II. Five patients have died-four in group I and one in group II. The actuarial survival rate at 15 mo was 75%. Early reoperations were frequent (69%), mainly caused by rebleeding. Bacterial and fungal infections occurred only in group Ia (four cases) and group II (three cases). In eight patients (palliative group), residual foci of infected nonhepatic tissue occurred after surgery. The titer of specific antibodies decreased during the first 3 mo in all the patients but one. In patients with radical liver transplantation, the complete disappearance of specific antibodies occurred within 2 yr in four cases. In the remaining five patients, specific antibodies remained detectable, but no evidence of recurrence has been obtained up to now. In the palliative group, a peak of specific IgM occurred at 3 mo; an increase of specific IgG was observed later. The growth of residual parasitic foci was relatively slow, and all these patients remained asymptomatic with a mean follow-up of 19 mo. We conclude that orthotopic liver transplantation is feasible in incurable alveolar echinococcosis and could be proposed without delay to patients with parasitic Budd-Chiari syndrome or complicated secondary biliary cirrhosis. In the other cases, the best time to perform an orthotopic liver transplantation is more difficult to determine. Nevertheless, in the perspective of an orthotopic liver transplantation, the management of these patients has to change, and repetitive laparotomies for palliative surgical procedures have to be replaced by interventional radiology.
1986年至1989年间,我们单位对17例无法治愈的肺泡型肝包虫病患者进行了原位肝移植。10例患者有肝门受累(I组),7例患者病变位于肝后部(其中5例患有慢性布-加综合征)(II组)。Ia组(6例患者)诊断至原位肝移植的间隔时间超过48个月,Ib组(4例患者)少于24个月,II组少于48个月。Ia组既往手术比Ib组和II组更常见。5例患者死亡,I组4例,II组1例。15个月时的精算生存率为75%。早期再次手术很常见(69%),主要原因是再次出血。细菌和真菌感染仅发生在Ia组(4例)和II组(3例)。8例患者(姑息治疗组)术后出现感染性非肝组织残留病灶。除1例患者外,所有患者的特异性抗体滴度在最初3个月内均下降。在接受根治性肝移植的患者中,4例患者的特异性抗体在2年内完全消失。其余5例患者仍可检测到特异性抗体,但目前尚未获得复发证据。在姑息治疗组,特异性IgM在3个月时达到峰值;随后观察到特异性IgG增加。残留寄生虫病灶生长相对缓慢,所有这些患者在平均19个月的随访中均无症状。我们得出结论,原位肝移植在无法治愈的肺泡型肝包虫病中是可行的,对于患有寄生虫性布-加综合征或复杂性继发性胆汁性肝硬化的患者可毫不犹豫地进行。在其他情况下,进行原位肝移植的最佳时机更难确定。然而,从原位肝移植的角度来看,这些患者的管理必须改变,姑息性手术的重复剖腹探查必须被介入放射学所取代。